Omeros (NASDAQ:OMER) Trading Up 6.4% – What’s Next?

Omeros Co. (NASDAQ:OMER) shares were up 6.4% on Thursday . The company traded as high as $8.96 and last traded at $9.07. Approximately 309,440 shares were traded during trading, a decline of 42% from the average daily volume of 530,454 shares. The stock had previously closed at $8.52.

Analyst Ratings Changes

A number of equities research analysts have issued reports on OMER shares. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Friday, January 17th. StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a report on Friday, March 21st. Finally, D. Boral Capital reiterated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Up 5.6 %

The stock has a market capitalization of $521.26 million, a PE ratio of -3.87 and a beta of 2.03. The business’s fifty day moving average is $8.71 and its two-hundred day moving average is $7.45.

Institutional Trading of Omeros

A number of large investors have recently made changes to their positions in the business. Two Sigma Investments LP grew its position in Omeros by 8.8% in the fourth quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after acquiring an additional 13,201 shares in the last quarter. ProShare Advisors LLC boosted its holdings in shares of Omeros by 75.0% in the 4th quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 7,927 shares during the period. Nomura Holdings Inc. increased its position in shares of Omeros by 136.2% during the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock valued at $7,383,000 after purchasing an additional 430,932 shares during the last quarter. Millennium Management LLC raised its holdings in Omeros by 46.2% during the 4th quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company’s stock valued at $846,000 after buying an additional 27,088 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Omeros by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 1,110 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.